ATRA
Atara Biotherapeutics, Inc.Company Information
- Company Name
- Atara Biotherapeutics, Inc.
- CIK
- CIK0001604464
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ATRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-04
- Last sale
- 2026-08-17
- Shares purchased (TTM)
- 611,573
- Shares sold (TTM)
- 416,536
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,429,148
- Shares outstanding
- 15,033,000
- Ownership
- 29.46%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 5.80%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 8 | 8 | 6 | 17 | 14 | 25 | 46 | 31 | 35 | 26 | 65 | ||||||
| Short Term Investments | 7 | - | 0 | 8 | 5 | 0 | 17 | 21 | 4 | 11 | 26 | 38 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 1 | 2 | 0 | 9 | 1 | 1 | 2 | 36 | 34 | 0 | ||||||
| Inventory Net | - | - | 0 | 0 | 0 | 0 | 11 | 14 | 19 | 16 | 10 | 7 | ||||||
| Other Assets Current | 3 | 4 | 2 | 3 | 2 | 4 | 10 | 9 | 6 | 8 | 6 | 9 | ||||||
| Assets Current | 14 | 12 | 12 | 18 | 25 | 27 | 65 | 92 | 62 | 106 | 102 | 119 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 4 | 5 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 7 | 11 | 11 | 32 | 40 | 46 | 49 | 52 | 55 | 59 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 5 | 6 | ||||||
| Assets | 21 | 20 | 20 | 30 | 37 | 62 | 109 | 143 | 117 | 165 | 166 | 189 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 0 | 2 | 1 | 4 | 2 | 5 | 3 | 4 | 7 | ||||||
| Employee Related Liabilities Current | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 8 | 7 | 6 | 12 | 14 | ||||||
| Deferred Income Current | 1 | 1 | 1 | 1 | 2 | 16 | 95 | 116 | 108 | 123 | 78 | 12 | ||||||
| Other Liabilities Current | 3 | 3 | 3 | 5 | 8 | 24 | 20 | 24 | 26 | 33 | 32 | 23 | ||||||
| Liabilities Current | 7 | 6 | 15 | 18 | 15 | 48 | 135 | 156 | 148 | 181 | 142 | 79 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 38 | 74 | ||||||
| Operating Lease Liability Noncurrent | 9 | 9 | 9 | 15 | 15 | 27 | 30 | 35 | 39 | 42 | 46 | 49 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | ||||||
| Liabilities | 58 | 57 | 59 | 67 | 72 | 117 | 206 | 233 | 228 | 264 | 265 | 240 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,994 | 1,989 | 1,983 | 1,982 | 1,979 | 1,961 | 1,957 | 1,951 | 1,909 | 1,903 | 1,870 | 1,858 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -2,031 | -2,026 | -2,022 | -2,018 | -2,014 | -2,017 | -2,055 | -2,042 | -2,020 | -2,001 | -1,969 | -1,909 | ||||||
| Stockholders Equity | -37 | -37 | -39 | -37 | -35 | -55 | -97 | -91 | -111 | -98 | -99 | -51 | ||||||
| Liabilities And Stockholders Equity | 21 | 20 | 20 | 30 | 37 | 62 | 109 | 143 | 117 | 165 | 166 | 189 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 9 | 9 | 7 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 4 | 4 | ||||||
| Shares Outstanding | 9 | 9 | 7 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAtara Biotherapeutics, Inc. (ATRA) — SEC Financial Statements & Analysis
Atara Biotherapeutics, Inc. (ATRA) is a biological products, (no diagnostic substances) company, incorporated in DE. Atara Biotherapeutics, Inc. trades on Nasdaq as: ATRA. Atara Biotherapeutics, Inc. (ATRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Atara Biotherapeutics, Inc. carries a market cap of $172.58M, a P/E ratio of -10.34x, a P/B ratio of -4.66x, a P/S ratio of 395.82x, an enterprise value of $169.36M, and an EV/EBITDA multiple of -12.01x. On profitability, it posts a gross margin of 747.71%, an operating margin of -3262.84%, a net margin of -3827.52%, a Return on Equity (ROE) of 46.33%, and a Return on Assets (ROA) of -57.62%. Per share, it reports EPS of $-1.11, diluted EPS of $-1.11, free cash flow per share of $-1.46, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -99.41% year-over-year, net income growth of -387.97% year-over-year, and EPS growth of -333.65% year-over-year. On the balance sheet, it maintains a current ratio of 1.98x, a quick ratio of 1.98x, working capital of $6.68M, a debt-to-equity ratio of -1.57x, a debt ratio of 2.76, an interest coverage ratio of -5.04x, free cash flow of $-21.89M (TTM), and net debt of $-3.22M. Figures sourced from SEC EDGAR.
- Market Cap
- $172.58M
- P/E TTM
- -10.34x
- EPS TTM
- $-1.11
- P/B TTM
- -4.66x
- ROE TTM
- 46.33%
- ROA TTM
- -57.62%
- Debt To Equity
- -1.57x
- Free Cash Flow TTM
- $-21.89M
- Net Revenue TTM Growth 1Y
- -99.41%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Atara Biotherapeutics, Inc. in?
Atara Biotherapeutics, Inc. (ATRA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ATRA trade on?
Atara Biotherapeutics, Inc. (ATRA) trades on the Nasdaq.
Where is Atara Biotherapeutics, Inc. incorporated?
Atara Biotherapeutics, Inc. is incorporated in DE.
When was Atara Biotherapeutics, Inc. (ATRA)'s most recent SEC filing?
Atara Biotherapeutics, Inc. (ATRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ATRA's market cap?
Atara Biotherapeutics, Inc. (ATRA) has a market capitalization of $172.58M as of 2026-06-30.
What is ATRA's EPS (earnings per share)?
Atara Biotherapeutics, Inc. (ATRA)'s trailing twelve month EPS is $-1.11 as of 2026-06-30.
What is ATRA's ROE (return on equity)?
Atara Biotherapeutics, Inc. (ATRA)'s trailing twelve month Return on Equity (ROE) is 46.33% as of 2026-06-30.
What is ATRA's ROA (return on assets)?
Atara Biotherapeutics, Inc. (ATRA)'s trailing twelve month Return on Assets (ROA) is -57.62% as of 2026-06-30.
What is ATRA's EV/EBITDA?
Atara Biotherapeutics, Inc. (ATRA)'s trailing twelve month EV/EBITDA is -12.01x as of 2026-06-30.